Xoma reported $-4766000 in EBITDA for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Agenus AGEN:US $ -34.34M 20.08M
Agios Pharmaceuticals AGIO:US $ -95.35M 3.32M
Biomarin Pharmaceutical BMRN:US $ 64.42M 7.75M
Bluebird Bio BLUE:US $ -99.42M 19.92M
Curis CRIS:US $ -15.02M 0.08M
Eli Lilly And LLY:US $ 1999.4M 1006.2M
Emergent Biosolutions EBS:US $ -27.5M 64.8M
Epizyme EPZM:US $ -49.63M 0.33M
Intercept Pharmaceuticals ICPT:US $ -10.87M 0.98M
Life Technologies LIFE:US $ -12.3M 3.76M
Macrogenics MGNX:US $ -38931000 24.79M
Novartis NVS:US $ 4660M 108M
Novartis NOVN:VX SF 4660M 108M
Pfizer PFE:US $ 12921M 1739M
Regeneron Pharmaceuticals REGN:US $ 1381.3M 20.4M
Teva Pharmaceutical Industries TEVA:US $ 1092M 20M
Xoma XOMA:US $ -4766000 2.7M
YTE INCY:US $ 276.8M 132.69M